Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old. (Q45921130)

17 December 2017

http://europepmc.org/abstract/MED/24442033

title

Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old. (English)

1 reference

17 December 2017

http://europepmc.org/abstract/MED/24442033

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Milena Gusella

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Antonio Bononi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yasmina Modena

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Laura Bertolaso

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Paola Franceschetti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Daniela Menon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Elisa Pezzolo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Carmen Barile

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Giorgio Crepaldi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Caterina Bolzonella

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Roberto Padrini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Felice Pasini

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

18 January 2014

1 reference

17 December 2017

http://europepmc.org/abstract/MED/24442033

published in

Cancer Chemotherapy and Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

517-524

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24442033%20AND%20SRC:MED&resulttype=core&format=json

Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Factors that may impact on immunosenescence: an appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Detection of DNA damage induced by topoisomerase II inhibitors, gamma radiation and crosslinking agents using the comet assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

The comet assay for DNA damage and repair: principles, applications, and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

DNA repair and aging in basal cell carcinoma: a molecular epidemiology study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Age and gender effects on DNA strand break repair in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z

Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2378-Z